Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 4/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797338 | 1.00 | PRMT5 (0.35) | PRMT5WDR77ADORA2APDE2ANT5E | |
| SCHEMBL1737327 | 0.87 | PRMT5 (0.41) | PRMT5WDR77 | |
| SCHEMBL1740336 | 0.86 | ADORA2A (0.32) | ADORA2APDE2ANT5EMMP1ADAM17 | |
| SCHEMBL6839945 | 0.85 | PRMT5 (0.32) | PRMT5WDR77MMP1ADAM17 | |
| SCHEMBL6455261 | 0.81 | MAPT (0.34) | PRMT5WDR77MMP1ADAM17 | |
| SCHEMBL6840048 | 0.81 | MGLL (0.33) | MMP1ADAM17 | |
| SCHEMBL1739713 | 0.78 | PRMT5 (0.37) | PRMT5WDR77 | |
| SCHEMBL3285867 | 0.78 | ADORA2A (0.33) | ADORA2APDE2ANT5E | |
| SCHEMBL1738563 | 0.78 | PRMT5 (0.38) | PRMT5WDR77 | |
| SCHEMBL4431815 | 0.77 | ADORA2A (0.42) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | RNASEH1, RNASE1, RNASEL | PRMT5 2966/4885WDR77 1841/4885ADORA2A 1134/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | PRMT5 3154/4885WDR77 1648/4885ADORA2A 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.